Vickers Vantage Corp. I (VCKA) to Combine with Scilex in $1.64B Deal
Vickers Vantage Corp. I (NASDAQ: VCKA) has entered into a definitive agreement to combine with commercial biopharmaceutical company Scilex, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), at a pro forma equity value of approximately $1.64 billion. The Palo Alto-based company focuses on the development and commercialization of non-opioid pain management products for treatmentRead More